- Title
- Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis
- Creator
- Kalincik, Tomas; Spelman, Timothy; Grand’Maison, Francois; La Spitaleri, Daniele; Rio, Maria Edite; Flechter, Sholmo; Oreja-Guevara, Celia; Giuliani, Giorgio; Savino, Aldo; Amato, Maria Pia; Petersen, Thor; Fernandez-Bolanos, Ricardo; Trojano, Maria; Bergamaschi, Roberto; Iuliano, Gerardo; Boz, Cavit; Lechner-Scott, Jeannette; Duquette, Pierre; Izquierdo, Guillermo; Grammond, Pierre; Lugaresi, Alessandra; Hupperts, Raymond; Cristiano, Edgardo; Van Pesch, Vincent
- Relation
- PloS One Vol. 8, Issue 5
- Publisher Link
- http://dx.doi.org/10.1371/journal.pone.0063480
- Publisher
- Public Library of Science
- Resource Type
- journal article
- Date
- 2013
- Description
- Objectives: To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Methods: Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. Results: Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as “lack of efficacy” (3.3% vs. 1.7%), “scheduled stop” (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. Conclusions: Treatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from “real-world” database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry.
- Subject
- multiple sclerosis; interferons; disabilities; magnetic resonance imaging; population groupings; prisms; statistical models; adverse events
- Identifier
- http://hdl.handle.net/1959.13/1039714
- Identifier
- uon:13691
- Identifier
- ISSN:1932-6203
- Language
- eng
- Full Text
- Reviewed
- Hits: 6100
- Visitors: 7238
- Downloads: 507
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT01 | Publisher version (open access) | 370 KB | Adobe Acrobat PDF | View Details Download |